It appears that pharma stocks fared better than medical device and biotech stocks. GlaxoSmithKline (NYSE:GSK) was down a mere 28 cents to close at $39.44 on Monday. Pfizer (NYSE:PFE) was down 45 cents to $16.66. Abbott Laboratories (NYSE:ABT), however, fared a little bit worse with its share price falling by $1.24 to close at $48.06.
In the world of medical devices, Boston Scientific (NYSE:BSX) came home least battered with its share price falling only 29 cents to close at $6. However, its single-digit stock price doesn’t really afford much comfort. Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ) both had reductions of more than $2 each to their share prices, which fell to $31.07 and $41.12 respectively. Stryker (NYSE:SYK) closed at $47.43 after a drop of $1.51, while Zimmer (NYSE:ZMH) was at $53.90, down $1.76.
Biotechnology stocks like Amgen (NASDAQ:AMGN) was cut to $49.88, a decline of $1.78 . Gilead Sciences (NASDAQ:GILD) slid only 22 cents to close at $36.82, while Biogen Idec (NASDAQ:BIIB) took a bigger hit dropping $3.29 to finish at $88.
These are just a sampling of some stocks in each sector and how they survived Manic Monday. Feel free to add how other stocks weathered the maelstrom in the comments section.